10-Q · May 15, 2026
KALA BIO's Q4 results exhibit a marked recovery in EPS, reporting $0.86 compared to a consensus estimate of -$0.77, leading to a notable EPS surprise of 2.1%. However, revenue remains at $0, indicating continued…
Earnings analysis · 10-Q
KALA earnings analysis
Filed August 19, 2026 · Our reading of the company's report
The latest report
The available 10-Q extract does not disclose current-period income-statement, segment, balance-sheet, or cash-flow results, so revenue, margin, EPS, and free-cash-flow trends cannot be assessed. The key development is…
Read full summary
The available 10-Q extract does not disclose current-period income-statement, segment, balance-sheet, or cash-flow results, so revenue, margin, EPS, and free-cash-flow trends cannot be assessed. The key development is negative control disclosure: management concluded that disclosure controls were ineffective as of June 30, 2026, and the material weakness previously identified in the 2025 Form 10-K remained un-remediated. Remediation activities have begun, while the company reports limited interest-rate sensitivity for its cash equivalents.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Remediation activities initiated
Management initiated remediation activities for the previously identified material weakness as of June 30, 2026, although the weakness remained un-remediated at that date.
-
Limited interest-rate exposure
The company states that an immediate 10% change in interest rates would not have a material effect on the fair market value of its cash equivalents because of their short-term maturities and fixed-income nature.
What to watch
-
Ineffective disclosure controls
Disclosure controls and procedures were concluded to be ineffective at the reasonable-assurance level as of June 30, 2026.
-
Unresolved internal-control weakness
The material weakness identified in the December 31, 2025 Form 10-K remained un-remediated as of June 30, 2026; the company attributes it to insufficient personnel following its restructuring and incomplete key controls over financial reporting.
-
Limited operating disclosure
The filing provides no current-period revenue, margin, EPS, cash-flow, balance-sheet, or segment figures in the available extract, limiting assessment of operating performance as of June 30, 2026.
Management's outlook
The provided filing extract contains no quantitative revenue or EPS outlook. Outlook was not provided in the available 10-Q text.
Earlier filings 4
10-K · April 15, 2026
KALA BIO's 2025 Form 10-K describes a strategic pivot from developing its MSC-S biologics program (KPI-012/KPI-014) to evaluating monetization of those assets while building an on‑premises AI research platform…
10-Q · November 19, 2025
KALA BIO reported a Q3 net loss of $7,564,000 (EPS -$1.07), an improvement from Q3 2024 loss of $8,950,000 (EPS -$1.93). Operating expenses declined to $7,239,000 from $9,988,000 a year earlier driven largely by a…
10-Q · May 14, 2025
Kala reported a smaller GAAP net loss of $8,947,000 for the quarter ended March 31, 2025 versus $11,807,000 in the prior-year quarter, driven by lower operating costs and higher grant income; net loss per share improved…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.